Pol F. Boudes

机构：Constellation Pharmaceuticals (United States) · ORCID：0000-0002-8654-0352

发表论文 105 篇 · 总被引 1999 次 · h-index 23

代表论文

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study (2023 · Hepatology · 被引 125)
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis (2022 · Journal of Hepatology · 被引 81)
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis (2023 · Alimentary Pharmacology & Therapeutics · 被引 23)
Development of AI Based Fibrosis Detection Algorithm by SHG / TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH (2025 · Liver International · 被引 13)
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study (2020 · Journal of Hepatology · 被引 10)
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018 · Journal of Hepatology · 被引 5)